NKGen Biotech secures $412,500 additional convertible funding from AlpineBrook Capital

NKGen Biotech and its operating subsidiary amended their secured convertible loan agreement to receive an additional $412,500 in funding from AlpineBrook Capital GP I Limited, with the lender receiving additional consideration shares and warrants. The capital injection suggests the biotech company is addressing near-term funding needs through debt financing rather than equity raises.